S Fazeli Farsani1, P C Souverein1, J A Overbeek2, M M J van der Vorst3, C A J Knibbe4,5, R M C Herings2,6, A de Boer1, A K Mantel-Teeuwisse1. 1. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands. 2. PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands. 3. Department of Paediatrics, St. Antonius Hospital, Nieuwegein, the Netherlands. 4. Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, the Netherlands. 5. Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands. 6. Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, the Netherlands.
Abstract
AIM: The aim of the study was to document long term trends in oral antidiabetic drug (OAD) use among children and adolescents in the Netherlands. METHODS: A population-based cohort study was conducted using the Dutch PHARMO Database Network. All patients younger than 20 years old with at least one OAD dispensing were identified. Age-adjusted and age-specific incidence (1999-2011) and prevalence (1998-2011) rates of OAD use were calculated. Trends over time were assessed using joinpoint regression software. A subset of PHARMO Database Network (including community pharmacy dispensing records linked to general practitioner data (OPD-GP database)) was used to assess indications for OADs. RESULTS: In 2011, the overall age-adjusted incidence and prevalence rates of OAD use were 20.7/100 000 (95% CI 19.2, 22.1) person-years (PY) and 53.8/100 000 (95% CI 51.5, 56.1) persons, respectively. The average annual percentage change (AAPC) in the overall age-adjusted incidence rates from 1999 to 2011 was 18.9% (95% CI 4.5, 35.2). The incidence and prevalence rates of OAD use were higher among females and older age categories. The increases in rates of OAD use were mainly driven by metformin. For only 50% of the 98 patients in the OPD-GP database, indications for OAD prescriptions were reported with type 1 diabetes (n = 20), type 2 diabetes (n = 16), and overweight/obesity (n = 10). CONCLUSIONS: Incidence and prevalence rates of OAD use in children and adolescents substantially increased in the Netherlands, especially among older age categories (10-14 and 15-19 years) and females. The main indications for use of OADs were type 1 and 2 diabetes and overweight/obesity.
AIM: The aim of the study was to document long term trends in oral antidiabetic drug (OAD) use among children and adolescents in the Netherlands. METHODS: A population-based cohort study was conducted using the Dutch PHARMO Database Network. All patients younger than 20 years old with at least one OAD dispensing were identified. Age-adjusted and age-specific incidence (1999-2011) and prevalence (1998-2011) rates of OAD use were calculated. Trends over time were assessed using joinpoint regression software. A subset of PHARMO Database Network (including community pharmacy dispensing records linked to general practitioner data (OPD-GP database)) was used to assess indications for OADs. RESULTS: In 2011, the overall age-adjusted incidence and prevalence rates of OAD use were 20.7/100 000 (95% CI 19.2, 22.1) person-years (PY) and 53.8/100 000 (95% CI 51.5, 56.1) persons, respectively. The average annual percentage change (AAPC) in the overall age-adjusted incidence rates from 1999 to 2011 was 18.9% (95% CI 4.5, 35.2). The incidence and prevalence rates of OAD use were higher among females and older age categories. The increases in rates of OAD use were mainly driven by metformin. For only 50% of the 98 patients in the OPD-GP database, indications for OAD prescriptions were reported with type 1 diabetes (n = 20), type 2 diabetes (n = 16), and overweight/obesity (n = 10). CONCLUSIONS: Incidence and prevalence rates of OAD use in children and adolescents substantially increased in the Netherlands, especially among older age categories (10-14 and 15-19 years) and females. The main indications for use of OADs were type 1 and 2 diabetes and overweight/obesity.
Authors: Roopa Kanakatti Shankar; Catherine Pihoker; Lawrence M Dolan; Debra Standiford; Angela Badaru; Dana Dabelea; Beatriz Rodriguez; Mary Helen Black; Giuseppina Imperatore; Andrew Hattersley; Sian Ellard; Lisa K Gilliam Journal: Pediatr Diabetes Date: 2012-10-10 Impact factor: 4.866
Authors: Antje Neubert; Yingfen Hsia; Lolkje T W de Jong-van den Berg; Katrin Janhsen; Gerd Glaeske; Kari Furu; Helle Kieler; Mette Nørgaard; Antonio Clavenna; Ian C K Wong Journal: Br J Clin Pharmacol Date: 2011-12 Impact factor: 4.335
Authors: Yingfen Hsia; Dalia Dawoud; Alastair G Sutcliffe; Russell M Viner; Sanjay Kinra; Ian C K Wong Journal: Br J Clin Pharmacol Date: 2012-01 Impact factor: 4.335
Authors: Krista L Lentine; Farrukh M Koraishy; Nagaraju Sarabu; Abhijit S Naik; Ngan N Lam; Amit X Garg; David Axelrod; Zidong Zhang; Gregory P Hess; Bertram L Kasiske; Dorry L Segev; Macey L Henderson; Allan B Massie; Courtenay M Holscher; Mark A Schnitzler Journal: Clin Transplant Date: 2019-09-08 Impact factor: 2.863
Authors: Anne van Rongen; Marloes P van der Aa; Maja Matic; Ron H N van Schaik; Vera H M Deneer; Marja M van der Vorst; Catherijne A J Knibbe Journal: Paediatr Drugs Date: 2018-08 Impact factor: 3.022
Authors: M P van der Aa; M A J Elst; E M W van de Garde; E G A H van Mil; C A J Knibbe; M M J van der Vorst Journal: Nutr Diabetes Date: 2016-08-29 Impact factor: 5.097